Beactica, the leading Swedish fragment-based drug discovery company, today announced the appointment of Dr Gisela Sitbon to its Board. Dr Sitbon, Deputy Region Director at Innovationsbron AB, brings more than 25 years experience from the life science industry within the areas of business development, R&D management and quality assurance to the Company.
“We are delighted to welcome Gisela to the Board of Beactica. Her combined business competence and experience in strategic planning for pharmaceutical R&D ventures will be of great value as Beactica continues to grow” said Dr Per Källblad, CEO of Beactica.
Gisela Sitbon commented: “Having followed Beactica closely since its start, I am excited to have the opportunity to help develop the Company. The combination of a value-generating discovery technology and a promising business model validated through deals with companies like GE Healthcare and Cubist Pharmaceuticals makes Beactica a company well worth keeping an eye on. I really look forward to join the Beactica Board.”
Dr Gisela Sitbon is Deputy Region Director Life Science at Innovationsbron AB, a company supporting the commercialization of innovations from industry and academia in Sweden. She is a non-executive member of the board at a number of companies and organisations including Industrifonden, Innoventus AB, NorDiag ASA. Through her own company, ZENZ Bioscience Partner AB, Gisela provides consultancy in the areas of business focusing and business development to high-growth companies. Gisela Sitbon worked for nearly ten years at Professional Genetics Laboratory AB in a number of senior rôles including Managing Director, Vice President Business Development and Head of Research & Development. At Karo Bio AB, the Swedish drug discovery and development company specializing in targeting nuclear receptors she held several managerial positions including Section Head and Project Director. Gisela gained her Doctorate of Medical Sciences from the Karolinska Institute in 1987.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 56 08 80.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the biophysical interaction of molecules in order to generate novel therapeutics. Beactica’s Sprint™ drug discovery platform efficiently integrates surface plasmon resonance (SPR) to accelerate the identification and optimization of high-quality lead compounds. The company was spun out of Uppsala University in August 2006. As well as building collaborations with external companies, Beactica is progressing its own drug discovery programmes of small molecule therapeutics. For more information about Beactica, please visit www.beactica.com.